fda status bpc-157 compounding 2026 ghk-cu approval 🚨 The FDA just changed the rules on peptides — effective BPC-157 FDA Status 2026: What

96374: Intravenous push, single or initial substance/drug 96375: Each additional sequential IV push of a new substance/drug 96376: Each additional IV push of the same drug, given at intervals of 30 minutes or more 96360 and 96361: These are for hydration therapy: 96360 Initial 31 minutes to 1 hour 96361 Each additional hour 90471: Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections)

While scientific interest continues to expand, BPC-157 remains a research compound and should only be used within appropriate laboratory environments by qualified professionals

Unlike GnRH agonists that create an artificial menopause to suppress estrogen, the weight-mediated estrogen reduction through GLP-1 agonists is more physiological

The Russian clinical trial context deserves specific mention